Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Cancer Profiling Market Growth From $16.67 Billion In 2026 To $25.62 Billion By 2030 At A CAGR Of 11.3%
The field of cancer profiling has witnessed substantial expansion lately. Projected to increase from a valuation of $15 billion in 2025 to $16.67 billion by 2026, this growth reflects a compound annual growth rate of 11.1%. Factors contributing to the expansion observed during the earlier period include a rise in cancer occurrences, a broader establishment of molecular diagnostics facilities, earlier integration of genetic testing within cancer care, an increase in research endeavors focused on cancer profiling, and the greater accessibility of diagnostic technologies.
The market for cancer profiling is poised for substantial expansion in the upcoming years, projecting a reach of $25.62 billion by 2030, propelled by a compound annual growth rate (CAGR) of 11.3%. This anticipated growth is largely fueled by a rising embrace of precision medicine strategies, the broadening scope of companion diagnostics, widespread adoption of liquid biopsy methods, escalating investments in cancer diagnostics, and the increasing incorporation of profiling into standard clinical practices. Key developments shaping this period include a greater reliance on next-generation sequencing (NGS) for cancer profiling, increased utilization of extensive genomic panels, enhanced integration of artificial intelligence for data analysis, the proliferation of personalized oncology diagnostics, and a heightened emphasis on identifying molecular markers early in the disease process.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp
Cancer Profiling Market Expansion Drivers: What Is Shaping Future Growth?
The projected rise in cancer occurrences is anticipated to fuel the expansion of the cancer profiling market in the future. Cancer incidence, signifying the count of new cancer diagnoses within a defined demographic over a specific timeframe, is escalating due to factors such as increasing urbanization, an aging global population, evolving lifestyle patterns, and a combination of environmental and hereditary influences. Cancer profiling serves a crucial role in pinpointing unique molecular or genetic alterations within a tumor, including gene mutations or other anomalies in tumor DNA, thereby contributing significantly to the cancer treatment continuum. For example, data from July 2024, citing the Australian Institute of Health and Welfare, a governmental body in Australia, indicated that an estimated 165,000 individuals in Australia received a new cancer diagnosis in 2023, translating to more than 450 diagnoses daily, with males accounting for approximately 55% of these cases. Consequently, the escalating rate of cancer incidence is a primary catalyst for the growth trajectory of the cancer profiling market.
Cancer Profiling Market Segment Breakdown: Which Categories Generate The Most Revenue?
The cancer profiling market covered in this report is segmented –
1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization
2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers
4) By Application: Research Applications, Clinical Applications, Diagnostics, Prognostics, Other Applications
Subsegments:
1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology
2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)
3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)
4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays
5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)
Cancer Profiling Market Strategic Trends: What Is Defining The Next Phase Of Growth?
To gain a competitive edge within the cancer profiling sector, leading companies are prioritizing innovations like integrated whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS) methodologies. These advanced assays are designed to deliver more thorough, tissue-efficient, and clinically relevant diagnostic insights for precision cancer treatment. By merging DNA (exome) and RNA (transcriptome) analysis into a singular process, these tests can identify both genetic alterations such as single nucleotide variants, insertions/deletions, and copy number variations, in addition to gene expression patterns or fusion events. This contrasts with older methods that either necessitated separate tests or were limited to examining only a select group of genes, thereby offering less comprehensive data. A notable development occurred in November 2024 when Caris Life Sciences, a US firm specializing in precision medicine, secured FDA clearance for MI Cancer Seek, an innovative next-generation sequencing in vitro diagnostic tool capable of performing WES and WTS concurrently. This particular assay leverages total nucleic acid extracted from formalin-fixed paraffin-embedded (FFPE) tumor samples to proficiently detect single nucleotide variants, insertions and deletions affecting 228 genes, microsatellite instability (MSI), tumor mutational burden (TMB), and copy number amplifications, specifically in breast cancer cases. The strategic advantage of consolidating both DNA and RNA profiling within a single examination lies in its capacity to conserve valuable tissue samples, provide actionable companion diagnostic (CDx) insights applicable to a diverse range of cancer types, and expedite the selection of therapeutic strategies by offering a unified genomic profile.
Cancer Profiling Market Key Players And Strategic Industry Positioning
Major companies operating in the cancer profiling market are Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation
Access The Complete Cancer Profiling Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report
Cancer Profiling Market Geographic Landscape: Which Region Dominates Industry Growth?
North Americawas the largest region in the cancer profiling market in 2025. The regions covered in the cancer profiling market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model